AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26571885
Drug: Floating-needle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floating-needle therapy combined with rehabilitation training
Trial: 24211338
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) + Light therapy (CBT + LT)
Trial: 17033231
Drug: UFT+TAM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT+TAM therapy
Trial: 17033231
Drug: CAF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF therapy
Trial: 9366769
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose in lactated Ringer's solution (D5RL)
Trial: 1412183
Drug: Warfarin, INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin, INR = 2.5 - 4.2 (n = 34)
Trial: 1412183
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA), 300 mg/d (n = 30)
Trial: 19357113
Drug: Pamapimod (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamapimod (up to 300 mg once daily)
Trial: 17022846
Drug: Rapidly absorbed
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapidly absorbed paracetamol tablet (PS)
Trial: 17022846
Drug: Standard paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard paracetamol tablet (P)
Trial: 15663607
Drug: Zolmitriptan 5
RxNorm normalized name: zolmitriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 5 mg nasal spray
Trial: 7490815
Drug: 5.4 mg
RxNorm normalized name: pectin 5.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.4 mg yohimbine plus 10 mg isoxsuprine 3 times daily
Trial: 7490815
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pentoxifylline 3 times daily
Trial: 1416272
Drug: Group EF:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group EF: 5 micrograms.kg‐1 of fentanyl followed by 0.3 mg.kg‐1 of etomidate.
Trial: 31704108
Drug: Fresh Empire
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh Empire campaign treatment
Trial: 25962788
Drug: Integrated motivational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated motivational interviewing and cognitive behavioural therapy
Trial: 17066118
Drug: Non-steroid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid group (combined Group I and II)
Trial: 17066118
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (combined Group III and IV)
Trial: 8446670
Drug: Ondansetron 0.15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15, 0.3, or 0.45 mg/kg
Trial: 8446670
Drug: Ondansetron 0.01,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.01, 0.02, or 0.04 mg/kg
Trial: 8446670
Drug: Ondansetron (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (various doses)
Trial: 2949169
Drug: Doxazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1 mg daily, titrated to double every two weeks)
Trial: 2949169
Drug: Doxazosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (8 weeks treatment)
Trial: 24518180
Drug: IDeg 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDeg 200 U/mL
Trial: 24518180
Drug: IDeg 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDeg 100 U/mL
Trial: 22983778
Drug: Titrated intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated intravenous norepinephrine (NE) infusion
Trial: 18042473
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate inhalation solution 20 microg BID via nebulizer (FFIS)
Trial: 7762533
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) for 6 months
Trial: 29931459
Drug: Vitamin D3,
RxNorm normalized name: Vitamin D3, 25 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3, 70 µg (2800 IU)/day for three months
Trial: 19923079
Drug: Coopdech endobronchial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coopdech endobronchial blocker tube (BB)
Trial: 17846932
Drug: Insulin only
RxNorm normalized name: Isophane insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin only (IO)
Trial: 17846932
Drug: Bedtime insulin
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime insulin with sulphonylurea (IS)
Trial: 17846932
Drug: Bedtime insulin
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime insulin with metformin (IM)
Trial: 12187213
Drug: Single 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 500 mg oral dose of levofloxacin
Trial: 12187213
Drug: Additional doses
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional doses of levofloxacin for high-risk patients
Trial: 10542974
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate (FP) 2000 micrograms daily via Diskhaler
Trial: 10542974
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 2000 micrograms daily via Turbuhaler
Trial: 23351277
Drug: Acetaminophen elixir
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen elixir (10-15 mg/kg)
Trial: 23351277
Drug: Acetaminophen suppository
RxNorm normalized name: acetaminophen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen suppository (10-15 mg/kg)
Trial: 19477353
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin daily for 12 weeks
Trial: 19477353
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atorvastatin daily for 12 weeks
Trial: 16451147
Drug: 80% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% oxygen in nitrogen and saline 2 ml intravenously (i.v.) at the end of surgery (group 80)
Trial: 16451147
Drug: 30% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oxygen in nitrogen and saline 2 ml intravenously (i.v.) at the end of surgery (group 30)
Trial: 16451147
Drug: 30% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oxygen in nitrogen and ondansetron 4 mg (group O)
Trial: 16451147
Drug: 80% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% oxygen in nitrogen and saline 2 ml intravenously (i.v.) (group 80)
Trial: 15225176
Drug: 3-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Trial: 15225176
Drug: 7-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Trial: 15225176
Drug: 10-day rabeprazole-based
RxNorm normalized name: rabeprazole sodium 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Trial: 15225176
Drug: 10-day omeprazole-based
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day omeprazole-based treatment (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Trial: 2286005
Drug: Sulfadoxine 25
RxNorm normalized name: pyrimethamine-sulfadoxine 25 mg-500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine 25 mg/kg + Pyrimethamine 1.25 mg/kg as a single dose (S + P)
Trial: 2286005
Drug: Amodiaquine 10
RxNorm normalized name: amodiaquine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine 10 + 10 + 5 mg/kg over three days with Sulfadoxine + Pyrimethamine on the third day (A + S + P)
Trial: 7015798
Drug: Methyldopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (250 mg thrice a day)
Trial: 27930383
Drug: E-OJ-01 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-OJ-01 (400 mg for 56 days)
Trial: 17952657
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of cannabinoids
Trial: 7924177
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 gm per day for 22 weeks)
Trial: 7924177
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs only (Control for subgroup A1)
Trial: 7924177
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 gm per day for 10 weeks)
Trial: 7924177
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs only (Control for subgroup A2)
Trial: 22538532
Drug: Aspirin 500
RxNorm normalized name: aspirin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 500 mg/d
Trial: 20826169
Drug: Protein-rich supplements
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-rich supplements (n=12)
Trial: 20826169
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (isocaloric combination of carbohydrate and fat supplements, n=4)
Trial: 11049908
Drug: Epinephrine-15 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine-15 group (3 mL of 1.5% lidocaine containing 15 microg of epinephrine)
Trial: 11049908
Drug: Epinephrine-10 group
RxNorm normalized name: epinephrine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine-10 group (2 mL of 1.5% lidocaine containing 10 microg of epinephrine)
Trial: 11049908
Drug: Epinephrine-5 group
RxNorm normalized name: epinephrine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine-5 group (1 mL of 1.5% lidocaine containing 5 microg of epinephrine)
Trial: 8922195
Drug: Vinorelbine (VRB)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (VRB) at a dose of 25 mg/m2 weekly
Trial: 8922195
Drug: Vindesine (VDS)
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (VDS) at a dose of 3 mg/m2 weekly
Trial: 2859900
Drug: Almitrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (3 mg X kg‐1)
Trial: 2859900
Drug: Almitrine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (1.5 mg X kg‐1 X day‐1) for four weeks
Trial: 24894625
Drug: Top 30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top 30% antibody responders with NicVAX
Trial: 24894625
Drug: Top 30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top 30% antibody responders with Placebo
Trial: 22722614
Drug: TENS vs
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS vs Acetaminophen
Trial: 20376002
Drug: Almorexant (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almorexant (doses of 400 mg and above)
Trial: 20376002
Drug: Almorexant (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almorexant (500 mg)
Trial: 12190961
Drug: Micronised oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised oestradiol (E2) 2 mg daily (n = 16)
Trial: 12190961
Drug: Combined HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined HRT (2 mg E2 daily with trimegestone 0.5 mg daily or dydrogesterone 10 mg daily) (n = 28)
Trial: 10208189
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (albuterol 10 mg/h plus ipratropium bromide 1.0 mg/h)
Trial: 10208189
Drug: Albuterol alone
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol alone (control)
Trial: 649240
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of papaverine
Trial: 649240
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml of physiological saline (placebo)
Trial: 15666492
Drug: Irbesartan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (300 mg/die)
Trial: 15666492
Drug: Chlortalidone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlortalidone (50 mg/die)
Trial: 12495257
Drug: Iron-folate tablets
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg riboflavin (group IFR)
Trial: 12495257
Drug: Iron-folate tablets
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 2.75 mg retinyl palmitate (equal to 5000 IU vitamin A) (group IFA)
Trial: 12495257
Drug: Iron-folate tablets
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg riboflavin + 2.75 mg retinyl palmitate (group IFRA)
Trial: 12495257
Drug: Iron-folate tablets
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg glucose (group IF)
Trial: 8595510
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 3TC (300 mg b.i.d.) plus AZT (200 mg t.i.d.) for 24 weeks
Trial: 8595510
Drug: AZT monotherapy
RxNorm normalized name: AZT
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZT monotherapy (200 mg t.i.d.)
Trial: 8595510
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 3TC (300 mg b.i.d.) plus AZT (200 mg t.i.d.)
Trial: 8595510
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 3TC (150 mg b.i.d.) plus AZT (200 mg t.i.d.)
Trial: 8595510
Drug: AZT monotherapy
RxNorm normalized name: AZT
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZT monotherapy (200 mg t.i.d. plus placebo)
Trial: 8595510
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with AZT and 3TC
Trial: 2651031
Drug: Multiple injection
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injection technique (MIT)
Trial: 28847751
Drug: GED‐0301 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GED‐0301 (160 mg/day) for 4 weeks
Trial: 28847751
Drug: GED‐0301 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GED‐0301 (160 mg/day) for 8 weeks
Trial: 28847751
Drug: GED‐0301 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GED‐0301 (160 mg/day) for 12 weeks
Trial: 11920488
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (40 mg genistein per day)
Trial: 6669927
Drug: Instilled fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instilled fluid volumes of 2.5, 5, 10, and 15 ml at pH 1.0, 4.0, or 7.0
Trial: 29176540
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (OCP)
Trial: 31843854
Drug: HealthTracker-based structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HealthTracker-based structured medication review tool
Trial: 22565284
Drug: CCCL ALL
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCCL ALL protocol (risk-adapted therapy)
Trial: 7750020
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin (100 IU/day i.m. plus 500 mg of elemental calcium for 10 days each month)
Trial: 7750020
Drug: Elemental calcium
RxNorm normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental calcium (500 mg for 10 days each month)
Trial: 2105985
Drug: Ketorolac 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 2% gel
Trial: 7041813
Drug: Cefonicid, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid, 1 g daily (21 cases)
Trial: 7041813
Drug: Cefamandole, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole, 1 g every 6 h (12 cases)
Trial: 31663620
Drug: DOX–MNPs treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOX–MNPs treatment
Trial: 31663620
Drug: Avasimibe combined
RxNorm normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe combined with DOX–MNPs treatment
Trial: 28009106
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 (high dose 1010 CFU/d)
Trial: 28009106
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 (low dose 108 CFU/d)
Trial: 25591799
Drug: Tivozanib 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 0.5 mg with mFOLFOX-6
Trial: 25591799
Drug: Tivozanib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 1.5 mg with mFOLFOX-6
Trial: 25618969
Drug: Xinfeng capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng capsules (XFC)
Trial: 10430010
Drug: Estriol suppositories
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol suppositories
Trial: 8685642
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg b.i.d. per os)
Trial: 8685642
Drug: Itraconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (100 mg b.i.d. per os)
Trial: 2097908
Drug: Midazolam 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.35 mg/kg (Group B)
Trial: 2097908
Drug: Midazolam 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.45 mg/kg (Group C)
Trial: 7439520
Drug: 2% fusidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% fusidic acid cream
Trial: 20361381
Drug: Pediatric granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric granule formulation of artesunate-mefloquine
Trial: 20361381
Drug: Co-blister tablet
RxNorm normalized name: Blister Armour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-blister tablet formulation
Trial: 16356228
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (blood glucose between 80 and 110 mg/dl)
Trial: 16356228
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy (blood glucose less than 200 mg/dl)
Trial: 12421159
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen (HBO treatment)
Trial: 12421159
Drug: 10% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% oxygen in nitrogen (hyperbaric normoxic placebo = sham treatment)
Trial: 10601381
Drug: Beta-carotene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (50 mg on alternate days, n = 19,939)
Trial: 10601381
Drug: Beta-carotene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (50 mg on alternate days) among smokers
Trial: 6996113
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (60 mg elemental iron)
Trial: 6996113
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (60 mg elemental iron) with riboflavin (6mg)
Trial: 29358012
Drug: Once-daily eliglustat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily eliglustat dosing
Trial: 29358012
Drug: Twice-daily eliglustat
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily eliglustat dosing
Trial: 29358012
Drug: Once-daily and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily and twice-daily dosing